An Open-Label, Multicenter, Phase 1 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Intravenous Doses of Inhibrx rhAAT-Fc (INBRX-101) in Adults with Alpha-1 Antitrypsin Deficiency (AATD)
R
Ryan Boente
Primary Investigator
Not Recruiting
18 years - 70 years
All
Phase
N/A
1 Location
Brief description of study
The purpose of the study is to assess safety and tolerability of a Phase I drug, INBRX-101 in patients with alpha-1 antitrypsin deficiency (AATD).
Detailed description of study
Here at IU Health, we are recruiting for clinical trial to study the effects of a new drug on Alpha-1 Antitrypsin Deficiency (AATD). All study procedures will take place at University Hospital at no cost to you. You will be compensated for your time and effort.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Alpha-1 Antitrypsin Deficiency (AATD)
-
Age: 18 years - 70 years
-
Gender: All
Inclusion Criteria
AATD diagnosis, willing to undergo 2 bronchoscopies
Non-smoker
Willing to hold current AATD treatment until study ends (about 5 months).
Non-smoker
Willing to hold current AATD treatment until study ends (about 5 months).
Updated on
01 Aug 2024.
Study ID: 1902734320
